biostudies-literatureGeiger RMIntramural FDA HHS1679626https://www.ebi.ac.uk/biostudies/studies/S-EPMC12690487biostudies-literatureUnknown5<h4>Background and purpose</h4>Nonclinical human cardiac new approach methodologies (NAMs), including human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) combined with multielectrode array (MEA) represent a highly predictive <i>in vitro</i> model for identifying drug-induced cardiac liabilities of individual drugs. Here, we extend the use of an <i>in vitro</i> cardiac NAM to evaluate the safety of a drug combination including moxifloxacin, an antibiotic, and QT prolonging drug, and cobicistat a pharmacokinetic booster shown to shorten repolarization <i>in vitro</i>.<h4>Methods</h4>To generate the <i>in vitro</i> cardiac NAM, MEA coupled with hiPSC-CMs were cultured for 7-8 days. Cells were treated with moxifloxacin and cobicistat individually or in combination and changeFrontiers in drug discoveryTowards human cardiac new approach methodologies (NAMs) to evaluate the combination of repolarization prolonging and shortening drugs: a pilot study.PMC12690487FD999999Geiger RMBhardwaj BBlinova KSerna CFeaster TKfalseTowards human cardiac new approach methodologies (NAMs) to evaluate the combination of repolarization prolonging and shortening drugs: a pilot study.<h4>Background and purpose</h4>Nonclinical human cardiac new approach methodologies (NAMs), including human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) combined with multielectrode array (MEA) represent a highly predictive <i>in vitro</i> model for identifying drug-induced cardiac liabilities of individual drugs. Here, we extend the use of an <i>in vitro</i> cardiac NAM to evaluate the safety of a drug combination including moxifloxacin, an antibiotic, and QT prolonging drug, and cobicistat a pharmacokinetic booster shown to shorten repolarization <i>in vitro</i>.<h4>Methods</h4>To generate the <i>in vitro</i> cardiac NAM, MEA coupled with hiPSC-CMs were cultured for 7-8 days. Cells were treated with moxifloxacin and cobicistat individually or in combination and change2025-01-01T00:00:00Z2025 Nov2026-06-06T13:56:23.865Z2026-05-31T03:09:58.944ZS-EPMC126904874138365710.3389/fddsv.2025.1679626